BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 26271155)

  • 1. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.
    Aghajanian C; Goff B; Nycum LR; Wang YV; Husain A; Blank SV
    Gynecol Oncol; 2015 Oct; 139(1):10-6. PubMed ID: 26271155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
    Aghajanian C; Blank SV; Goff BA; Judson PL; Teneriello MG; Husain A; Sovak MA; Yi J; Nycum LR
    J Clin Oncol; 2012 Jun; 30(17):2039-45. PubMed ID: 22529265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
    Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
    Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer.
    Aghajanian C; Goff B; Nycum LR; Wang Y; Husain A; Blank S
    Gynecol Oncol; 2014 Apr; 133(1):105-10. PubMed ID: 24508841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.
    Fuh KC; Secord AA; Bevis KS; Huh W; ElNaggar A; Blansit K; Previs R; Tillmanns T; Kapp DS; Chan JK
    Gynecol Oncol; 2015 Dec; 139(3):413-8. PubMed ID: 26144600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
    Pfisterer J; Shannon CM; Baumann K; Rau J; Harter P; Joly F; Sehouli J; Canzler U; Schmalfeldt B; Dean AP; Hein A; Zeimet AG; Hanker LC; Petit T; Marmé F; El-Balat A; Glasspool R; de Gregorio N; Mahner S; Meniawy TM; Park-Simon TW; Mouret-Reynier MA; Costan C; Meier W; Reinthaller A; Goh JC; L'Haridon T; Baron Hay S; Kommoss S; du Bois A; Kurtz JE;
    Lancet Oncol; 2020 May; 21(5):699-709. PubMed ID: 32305099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study).
    Fujiwara H; Ushijima K; Nagao S; Takei Y; Shimada M; Takano M; Yoshino K; Kawano Y; Hirashima Y; Nagase S; Nishio S; Nishikawa T; Ito K; Shoji T; Kimura E; Takano T; Sugiyama T; Kigawa J; Fujiwara K; Suzuki M
    Int J Clin Oncol; 2019 Oct; 24(10):1284-1291. PubMed ID: 31127479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer.
    Eisenhauer EL; Zanagnolo V; Cohn DE; Salani R; O'Malley DM; Sutton G; Callahan MJ; Cobb B; Fowler JM; Copeland LJ
    Gynecol Oncol; 2014 Aug; 134(2):262-6. PubMed ID: 24910452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer.
    Vergote I; Heitz F; Buderath P; Powell M; Sehouli J; Lee CM; Hamilton A; Fiorica J; Moore KN; Teneriello M; Golden L; Zhang W; Pitou C; Bell R; Campbell R; Farrington DL; Bell-McGuinn K; Wenham RM
    Gynecol Oncol; 2020 Jan; 156(1):23-31. PubMed ID: 31791552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients.
    Safra T; Asna N; Veizman A; Shpigel S; Matcejevsky D; Inbar M; Grisaru D
    Anticancer Drugs; 2014 Mar; 25(3):340-5. PubMed ID: 24185383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.
    Ledermann JA; Embleton AC; Raja F; Perren TJ; Jayson GC; Rustin GJS; Kaye SB; Hirte H; Eisenhauer E; Vaughan M; Friedlander M; González-Martín A; Stark D; Clark E; Farrelly L; Swart AM; Cook A; Kaplan RS; Parmar MKB;
    Lancet; 2016 Mar; 387(10023):1066-1074. PubMed ID: 27025186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Adding Bevacizumab to Paclitaxel + Carboplatin for Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: A Propensity Score Matching Analysis.
    Hirasawa T; Machida H; Iida T; Ikeda M; Shida M; Mikami M
    Tokai J Exp Clin Med; 2018 Sep; 43(3):85-89. PubMed ID: 30191541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
    Pignata S; Lorusso D; Joly F; Gallo C; Colombo N; Sessa C; Bamias A; Salutari V; Selle F; Frezzini S; De Giorgi U; Pautier P; Bologna A; Orditura M; Dubot C; Gadducci A; Mammoliti S; Ray-Coquard I; Zafarana E; Breda E; Favier L; Ardizzoia A; Cinieri S; Largillier R; Sambataro D; Guardiola E; Lauria R; Pisano C; Raspagliesi F; Scambia G; Daniele G; Perrone F;
    Lancet Oncol; 2021 Feb; 22(2):267-276. PubMed ID: 33539744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
    Kim SI; Lee EJ; Lee M; Chung H; Kim JW; Park NH; Song YS; Kim HS
    Int J Gynecol Cancer; 2020 Dec; 30(12):1943-1950. PubMed ID: 33055266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
    Coleman RL; Spirtos NM; Enserro D; Herzog TJ; Sabbatini P; Armstrong DK; Kim JW; Park SY; Kim BG; Nam JH; Fujiwara K; Walker JL; Casey AC; Alvarez Secord A; Rubin S; Chan JK; DiSilvestro P; Davidson SA; Cohn DE; Tewari KS; Basen-Engquist K; Huang HQ; Brady MF; Mannel RS
    N Engl J Med; 2019 Nov; 381(20):1929-1939. PubMed ID: 31722153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of recurrent ovarian cancer.
    Pignata S; C Cecere S; Du Bois A; Harter P; Heitz F
    Ann Oncol; 2017 Nov; 28(suppl_8):viii51-viii56. PubMed ID: 29232464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
    del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
    Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10.
    Hong SH; Lee S; Kim HG; Lee HJ; Jung KH; Lee SC; Lee NR; Yun J; Woo IS; Park KH; Kim KH; Kim HY; Rha SY; Byun JH
    Gynecol Oncol; 2015 Feb; 136(2):212-7. PubMed ID: 25462205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
    Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
    Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
    Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W
    Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.